

REMARKS

The Restriction Requirement among Groups I, II, IV, is respectfully traversed, as the claims in Group I, based on claim 1, are directed to multicomponent vaccines comprising at least six clostridial organisms and least one non-clostridial organism's antigen and the claims in Group II comprise at least seven clostridial organisms and at least one non-clostridial organism's antigen. Similarly, Group IV, claim 42, is directed to a vaccine comprising six clostridial organisms specifically named and a protective antigen from four specific viruses. The claims in Group II and Group IV differ from Group I only by adding at least one additional clostridial organism to the six comprised in the originally claimed vaccine and, in the case of claim 42, the six specific clostridial organisms in the claimed vaccine are identified as well as four specific viruses as antigenic components from "at least one non-clostridial organism."

In view of the above comments, for clarity, claim 2 is now made dependent on claim 1.


With the present amendments it is believed that all claims except group III, claim 41, should clearly be examined in the present application.

-10-

Attorney Docket: J-95.184 US D1
 USSN: 10/748,524

Favorable action is solicited. In the event any fees are required with this paper, please charge our Deposit Account No. 02-2334.

Respectfully submitted,



William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Akzo Nobel Pharma Patent Dept.
29160 Intervet Lane
P.O. Box 318
Millsboro, DE 19966
DE Tel: (302) 934-4317
MD Tel: (410) 464-0581
Fax: (302) 934-4305

-11-

Attorney Docket: I-95.184 US D1
USSN: 10/748,524